Prevention and treatment for epstein-barr virus infection and related cancers

Recent Results in Cancer Research

Volumn 193, Issue , 2014, Pages 173-190

  Smets, Françoise ^a   Sokal, Etienne M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cancer; Cell therapy; Epstein Barr virus (EBV); Post transplant lymphoproliferative diseases (PTLD); Specific immunity; Viral load

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN BARR VIRUS VACCINE; GANCICLOVIR; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYTARABINE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IMMUNOGLOBULIN A ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID; RAPAMYCIN; VIRUS DNA;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ARTICLE; BURKITT LYMPHOMA; CANCER PREVENTION; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG FATALITY; EPSTEIN BARR VIRUS INFECTION; GRAFT REJECTION; HODGKIN DISEASE; HUMAN; INFECTION; INFECTION PREVENTION; LEUKOPENIA; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NATURAL KILLER T CELL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CARCINOMA; VIRUS LOAD; VIRUS REACTIVATION; ADOPTIVE IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; STEM CELL TRANSPLANTATION;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NEOPLASMS;

EID: 84958247566     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-38965-8_10     Document Type: Article

References (78)

1. Ansell SM (2012) Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 87:1096-11033
2. Bacigalupo A, Socie G, Lanino E et al (2010) Fludarabine, cyclophosphamide antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematol 95:976-9822
3. Bakker NA, van Imhoff GW, Verschuuren EAM et al (2007) Presentation and early detection of post-transplant lymphoproliferative disorder after solid transplantation. Transpl Int 20:207-2188
4. Bingler MA, Feingold B, Miller SA et al (2008) Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 8:442-4455
5. Bollard CM, Rooney CM, Heslop HE (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9:510-5199
6. Cao SM, Simons MJ, Qian CN (2011) The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 30:114-1199
7. Cen O, Longnecker R (2011) Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma. Mol Cancer Ther 10:679-6866
8. Chang MS, Kim WH (2005) Epstein-Barr virus in human malignancy: a special reference to Epstein-Barr virus associated gastric carcinoma. Cancer Res Treat 37:257-2677
9. Chen JN, He D, Tang F et al (2012) Epstein-Barr virus-associated gastric carcinoma: a newly defined entity. J Clin Gastroenterol 46:262-2711
10. Cockfield SM (2001) Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3:70-788
11. Cohen JI (1999) The biology of Epstein-Barr virus: lessons learned from the virus and the host. Curr Opin Immunol 11:365-3700
12. Cohen JI, Fauci AS, Varmus H et al (2011) Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 3:107fs77
13. D'Antiga L, Del Rizzo M, Mengoli C et al (2007) Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transplant 13:343-3488
14. Dominietto A, Tedone E, Soracco M et al (2012) In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 47:101-1066
15. Doubroniva E, Oflaz-Sozmen B, Prockop SE et al (2012) Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV ? lymphomas after allogeneic hematopoietic cell transplantation. Blood 119:2644-26566
16. Elliott SL, Suhrbier A, Miles JJ et al (2008) Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82:1448-14577
17. Evens AM, David KA, Helenowski I et al (2010) Multicenter analysis of 80 solid organ transplantation recipients with post-transplant lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 28:1038-10466
18. Fukayama M, Ushiku T (2011) Epstein-Barr virus-associated gastric carcinoma. Pathol Res Pract 207:529-5377
19. Funch DP, Walker AM, Schneider G et al (2005) Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5:2894-29000
20. Gotoh K, Ito Y, Ohta R et al (2010) Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. J Infect Dis 202:461-4699
21. Gross TG, Bucavals JC, Park JR et al (2005) Low-dose chemotherapy for Epstein-Barr viruspositive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 23:6481-64888
22. Gross TG, Orjuela MA, Perkins SL et al (2012) Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a children's oncology group report. Am J Transplant 12:3069-30755
23. Gulley ML, Tang W (2010) Using Epstein-Barr load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 23:350-3666
24. Heslop HE (2009) How I treat EBV lymphoproliferation. Blood 114:4002-40088
25. Heslop HE (2012) Equal-opportunity treatment of EBV-PTLD. Blood 119:2436-24388
26. Hierro L, Diez-Dorado R, Diaz C et al (2008) Efficacy and safety of valganciclovir in livertransplanted children infected with Epstein-Barr virus. Liver Transpl 14:1185-11933
27. Hoegh-Petersen M, Goodyear D, Geddes MN et al (2011) High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplant 46:1104-11122
28. Iwata S, Saito T, Ito Y et al (2012) Antitumor activities of valproic acid on Epstein-Barr virusassociated T and natural killer lymphoma cells. Cancer Sci 103:375-3811
29. Johannessen I, Bieleski L, Urquhart G et al (2011) Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo. J Med Virol 83:1585-15966
30. Kamdar KY, Rooney CM, Heslop HE (2011) Post-transplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant 16:274-2800
31. KDIGO Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9:S1-S1555
32. Kerkar N, Morotti RA, Madan RP et al (2010) The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant 14:504-5111
33. Kimura H, Ito Y, Kawabe S et al (2012) EBV-associated T/NK cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 119:673-6866
34. Kindwall-Keller TL, Cooper BW, Laughlin MJ et al (2009) Preemptive rituximab treatment may reduce the incidence of post-transplant lymphoproliferative disorders (PTLD) in patients with EBV reactivation after allogeneic stem cell transplantation (Abstract). Biol Blood Marrow Transplant 15:911
35. Landgren O, Gilbert ES, Rizzo JD et al (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113:4992-50011
36. Lee AWM, Ng WT, Chan YH et al (2012a) The battle against nasopharyngeal cancer. Radiother Oncol 104:272-2788
37. Lee HL, Kim DC, Lee SP et al (2012b) Treatment of Epstein-Barr virus-associated gastric carcinoma with endoscopic submucosal dissection. Gastrointest Endosc 76:913-9155
38. Lee TC, Savoldo B, Rooney CM et al (2005) Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 5:2222-22288
39. Lee TC, Goss JA, Rooney CM et al (2006a) Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 20:689-6944
40. Lee TC, Savoldo B, Barshes NR et al (2006b) Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant 20:389-3933
41. Leen AM, Christin A, Myers GD et al (2009) Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114:4283-42922
42. Liebowitz D (1998) Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338:1413-14211
43. Liu X, Wang Y, Wang X et al (2012) Epigenetic silencing of WNT5A in Epstein-Barr virusassociated gastric carcinoma. Arch Virol. doi:10.1007/s00705- 012-1481-xx
44. Long HM, Taylor GS, Rickinson AB (2011) Immune defence against EBV and EBV-associated disease. Curr Opin Immunol 23:258-2644
45. Lynch BA, Vasef MA, Comito M et al (2003) Post transplant lymphoproliferative disorder. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation. Bone Marrow Transplant 32:527-5333
46. Miles RR, Arnold S, Cairo MS (2012) Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol 156:730-7433
47. Montserrat E (2012) PTLD treatment: a step forward, a long way to go. Lancet Oncol 13:120-1211
48. Murphy G, Pfeiffer R, Camargo MC et al (2009) Meta-analysis shows that prevalence of Epstein- Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137:824-8333
49. Okano M, Gross TG (2012) Acute or chronic life treatening diseases associated with Epstein-Barr virus infection. Am J Med Sci 343:483-4899
50. Parker A, Bowles K, Bradley JA et al (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS guidelines. Br J Haematol 149:693-7055
51. Reddy N, Rezvani K, Barrett AJ et al (2011) Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 17:591-5977
52. Rickinson AB (1998) Epstein-Barr virus in action in vivo. N Engl J Med 338:1461-14622
53. Savani BN, Pohlmann PR, Jagasia M et al (2009) Does peritransplant use of rituximab reduce the risk of EBV reactivation and PTLPD? Blood 113:6263-62644
54. Schiller JT, Lowy DR (2010) Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 64:23-411
55. Sebelin-Wulf K, Nguyen TD, Oertel S et al (2007) Quantitative analysis of EBV-specific CD4/ CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PTLD. Transplant Immunol 17:203-2100
56. Seo JS, Kim TG, Hong YS et al (2011) Contribution of Epstein-Barr virus infection to chemoresistance of gastric carcinoma cells to 5-fluorouracil. Arch Pharm Res 34:635-6433
57. Shin HJ, Kim DN, Lee SK (2011) Association between Epstein-Barr virus infection and chemoresistance to docetaxel in gastric carcinoma. Mol Cells 32:173-1799
58. Smets F, Sokal EM (2002a) Lymphoproliferation in children after liver transplantation. J Pediatr Gastroenterol Nutr 34:499-5055
59. Smets F, Sokal EM (2002b) Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis and management. Pediatr Transplant 6:280-2877
60. Smets F, Bodeus M, Goubau P et al (2000) Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients. J Hepatol 32:100-1044
61. Smets F, Latinne D, Bazin H et al (2002) Ratio between Epstein-Barr viral load and anti-Epstein- Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73:1603-16100
62. Sokal EM, Hoppenbrouwers K, Vandermeulen C et al (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196:1749-17533
63. Stern M, Opelz G, Döhler B et al (2010) Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood 115:3960-39655
64. Steven NM (1997) Epstein-Barr virus latent infection in vivo. Rev Med Virol 7:97-1066
65. Styczynski J, Einsele H, Gil L et al (2009a) Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 11:383-3922
66. Styczynski J, Reusser P, Einsele H et al (2009b) Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second European conference on infections in leukemia. Bone Marrow Transplant 43:757-7700
67. Swerdlow SH, Campo E, Jaffe ES et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon
68. Trappe R, Oertel S, Leblond V et al (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13:196-2066
69. Truong CD, Feng W, Li W et al (2009) Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in USA. J Exp Clin Cancer Res 28:14-222
70. Vianna RM, Mangus RS, Fridell JA et al (2008) Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation 85:1290-12933
71. Vogl BA, Fagin U, Nerbas L et al (2012) Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation. J Med Virol 84:119-1311
72. Wagner HJ, Wessel M, Jabs W et al (2001) Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 72:1012-10199
73. Wang Q, Liu H, Zhang X et al (2010) High doses of mother's lymphocyte infusion to treat EBVpositive T-cell lymphoproliferative disorders in childhood. Blood 116:5941-59477
74. Weiner C, Weintraub L, Wistinghausen B et al (2012) Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease. Pediatr Transplant 16:458-4644
75. Wiesmayr S, Webber SA, Macedo C (2012) Decreased NKp46 and NKG2D and elevated PD-11 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol 42:541-5500
76. Williams H, McAuley K, Macsween KF et al (2005) The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol 129:266-2744
77. Worth A, Conyers R, Cohen J et al (2011) Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 155:377-3855
78. Zhao J, Jin H, Cheung KF et al (2012) Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer. Cancer 118:924-9366